An expedient synthesis of new 2-(furoxan-3-yl)thiazolidin-4-one derivatives

Singam Naveen Kumar,^a Chebolu Naga Sessa Sai Pavan Kumar,^{*a,c}
Sri Ranga Vanarasi Anudeep,^a Kirti Kumari Sharma,^{a,b} Vaidya Jayathirtha Rao,^{a,b}
and Nanubolu Jagadeesh Babu^d

^a Crop Protection Chemicals Division, Indian Institute of Chemical Technology,
Uppal Road Tarnaka, Hyderabad 500 007, Telangana, India

^b AcSIR-IICT, CSIR-Indian Institute of Chemical Technology, Uppal Road Tarnaka,
Hyderabad 500 007, Telangana, India

^c Division of Chemistry, Department of Sciences and Humanities,
Vignan's Foundation for Science, Technology & Research, Vignan University,
Vadlamudi, Guntur 522 213, Andhra Pradesh, India

^d Laboratory of X-ray Crystallography, Indian Institute of Chemical Technology,
Hyderabad 500 007, India.

E-mail: pavaniict@gmail.com

DOI: <http://dx.doi.org/10.3998/ark.5550190.p009.669>

Abstract

A series of new biologically interesting furoxan-3-thiazolidinones have been synthesized *via* one-pot three-component reaction of furoxan aldehydes, anilines and mercaptoacetic acid. The multi-component reaction involves condensation of furoxan aldehyde with aniline to give imine; the formed imine undergoes nucleophilic addition with mercaptoacetic acid, followed by cyclisation with loss of H₂O to obtain the desired products. All the synthesized compounds were well characterized using spectral techniques and confirmed by an X-ray crystal structure for one compound.

Keywords: Furoxan-3-carbaldehydes, One-pot reaction, thiazolidin-4-ones, crystal structure

Introduction

To fight against disease, society depends on the development of new biologically active compounds. One of the new approaches towards this goal is the development of hybrid heterocyclic compounds. A large number of chemical libraries can be accessed by the combination

of different heterocycles and they may be considered to be valuable as they incorporate classes of compound with proven utility in medicinal chemistry.

Furoxans (1,2,5-oxadiazole 2-oxides) are a class of five membered heterocyclic compounds having oxygen and nitrogen as heteroatoms. They constitute an important class of heterocyclic compounds possessing biological activities such as antihelmintic, antitumor, antimicrobial, mutagenic, immunosuppressive, anticancer, and anti-aggregating properties.¹⁻³ Some furoxan derivatives shown potential cardiovascular properties.⁴ Furthermore, furoxans are well known as NO-donors, and recently furoxan compounds have shown activity against schistosomiasis.⁵ Furoxans are also used in combination with drugs as NO donor-drug hybrids. α 1-Antagonists, β 1-antagonists, Ca^{2+} -channel blockers, K^{+} -channel activators, NSAIDs, and H3- and H2-antagonists are a few examples having NO donor-drug hybrids.⁶ NO donor-1,4-dihydropyridine also proved to be Ca^{2+} -channel activators.⁷ Furthermore, REC15/2739, a uroselective α 1-antagonist,⁸ and Rabeprazole, a potent inhibitor of $\text{H}^{+}/\text{K}^{+}$ -ATPase enzyme,⁹ are also NO donor-drugs.

Thiazolidinones and related structures are present in natural products; they have a wide range of biological activities and comprise an important motif in pharmaceutical compounds.¹⁰⁻¹³ Thiazolidinones and their derivatives have been reported to possess anticonvulsant,¹⁴⁻¹⁶ antifungal,¹⁷⁻¹⁹ antitubercular,^{20,21} antitumour,²² antiparasitic,²³ herbicidal,²⁴ anti-inflammatory,²⁵ analgesic,²⁶ anticancer,^{27,28} antibacterial,²⁹⁻³¹ and antipsychotic³² properties. They have also been reported to inhibit the bacterial enzyme Mur-B, a precursor in the biosynthesis of peptidoglycon, which is a non-nucleoside inhibitor of HIV-RT.^{33,34} Motivated by these findings, and in continuation of our ongoing efforts towards with the discovery of nitrogenated heterocycles with potential chemotherapeutic activities,^{35,36} we planned to synthesize a new series of hybrid furoxan-3-thiazolidinone derivatives of potential biological activity.

Results and Discussion

The present work was designed to synthesize new furoxan-3-thiazolidinones from substituted furoxan aldehydes (**4a-c**). The synthetic scheme was depicted in Scheme 1. The vital intermediates, furoxan aldehydes **4a-c**, were synthesized following a known route from substituted benzaldehydes. Horner Wadsworth Emmons reaction of benzaldehydes in the presence of NaH as a base yielded substituted ethyl cinnamates **1a-c**. The ethyl cinnamates were subjected to DIBAL-H reduction to yield cinnamyl alcohols **2a-c**. Further, the cinnamyl alcohols were treated with aq. NaNO_2 in the presence of glacial acetic acid to obtain furoxan methanol derivatives **3a-c**.³⁷ Oxidation of the alcohol functionality of the furoxanmethanols using MnO_2 yielded furoxan aldehydes **4a-c** in excellent yields.³⁷ Finally, a one-pot three component reaction of furoxan aldehydes **4a-c** with substituted anilines **6a-n** and mercaptoacetic acid **5** was achieved by simple heating in toluene at 50 °C to obtain the required furoxan-3-thiazolidinones **7a-n**, **8a-n**, **9a-n** in good yields.

Reagents and conditions: *a* $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{COOEt}$, NaH, DCM, 0 °C-rt, 1 h, 85-90%. *b* DIBAL-H, DCM, 0 °C, 4 h. *c* Acetic acid, aq. NaNO_2 , rt, 4-6 h, 30-75%. *d* MnO_2 , CH_2Cl_2 , 2-4h, 85-95% *e* Toluene, 50 °C, 4 h, 70-84%.

Scheme 1. The preparation of furoxanyl thiazolidinones **7-9**.

Multi-component reaction (MCR) involves three main steps. In step 1, the condensation of furoxan aldehyde with aniline forms imine I; the imine undergoes nucleophilic addition with mercaptoacetic acid to give intermediate II (step 2), followed by cyclisation (by loss of H_2O) to give the final product (step 3) as shown in Scheme 2. All the synthesized compounds are listed in Table 1.

The structural connectivity of the furoxan thiazolidinones is confirmed by a single-crystal X-ray diffraction analysis of compound **7g**, as shown in Figure 1.

Scheme 2. Suggested pathway to thiazolidinone ring formation.

X-ray Crystallographic analysis^{38,39}

Data for **7g**, a colorless crystal compound, molecular weight: $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_4\text{S}$, $M = 369.394$, colorless block, $0.38 \times 0.34 \times 0.26 \text{ mm}^3$, monoclinic, space group $P2_1/n$ (No. 14), $a = 8.9714(7)$, $b = 16.3622(13)$, $c = 11.8077(9) \text{ \AA}$, $\beta = 98.4520(10)^\circ$, $V = 1714.4(2) \text{ \AA}^3$, $Z = 4$, $D_c = 1.431 \text{ g/cm}^3$, $F_{000} = 768$, CCD area detector, MoK α radiation, $\lambda = 0.71073 \text{ \AA}$, $T = 293(2) \text{ K}$, $2\theta_{\text{max}} = 50.0^\circ$, 16244 reflections collected, 3020 unique ($R_{\text{int}} = 0.0192$), Final $Goof = 1.030$, $R1 = 0.0312$, $wR2 = 0.0845$, R indices based on 2767 reflections with $I > 2\sigma(I)$ (refinement on F^2), 237 parameters, $\mu = 0.219 \text{ mm}^{-1}$.

Figure 1. ORTEP diagram of the compound **7g**.

Table 1. One-pot synthesis of 2-(furoxan-3-yl)thiazolidin-4-ones

Entry	Furoxan aldehyde	Substituted Aniline	Product	Isolated yield (%)	Melting point (°C)
1	4a	R'=H (6a)	R, R' = H (7a)	82	82-84
2	4a	R'=4- <i>n</i> -Bu (6b)	R=H; R'= 4- <i>n</i> -Bu (7b)	77	100-102
3	4a	R'=4- <i>i</i> -Pr (6c)	R=H; R'=4- <i>i</i> -Pr (7c)	75	160-164
4	4a	R'=4- <i>t</i> -Bu (6d)	R=H; R'=4- <i>t</i> -Bu (7d)	81	150-152
5	4a	R'=3,5-diMe (6e)	R=H; R'=3,5-diMe (7e)	78	160-161
6	4a	R'=3,4-diMe (6f)	R=H; R'=3,4-diMe (7f)	78	145-147
7	4a	R'=4-OMe (6g)	R=H; R'=4-OMe (7g)	78	129-131
8	4a	R'=3,4-diOMe (6h)	R=H; R'=3,4-diOMe (7h)	77	120-124
9	4a	R'=3,4-OCH ₂ O (6i)	R=H; R'=3,4-OCH ₂ O (7i)	77	121-123
10	4a	R'=3-F (6j)	R=H; R'=3-F (7j)	77	99-101

Table 1 (continued)

Entry	Furoxan aldehyde	Substituted Aniline	Product	Isolated yield (%)	Melting point (°C)
11	4a	R'=4-F (6k)	R=H; R'=4-F (7k)	77	118-120
12	4a	R'=3-Cl (6l)	R=H; R'=3-Cl (7l)	80	108-110
13	4a	R'=4-Cl (6m)	R=H; R'=4-Cl (7m)	81	158-159
14	4a	R'=4-Br (6n)	R=H; R'=4-Br (7n)	70	198-200
15	4b	R'=H (6a)	R=OMe R' = H (8a)	80	150-152
16	4b	R'= 4- <i>n</i> -Bu (6b)	R= OMe; R'= 4- <i>n</i> -Bu (8b)	81	99-100
17	4b	R'=4- <i>i</i> -Pr (6c)	R= OMe; R'=4- <i>i</i> -Pr (8c)	77	125-127
18	4b	R'=4- <i>t</i> -Bu (6d)	R= OMe; R'=4- <i>t</i> -Bu (8d)	81	126-128
19	4b	R'=3,5-diMe (6e)	R= OMe; R'=3,5-diMe (8e)	84	128-130
20	4b	R'=3,4-diMe (6f)	R= OMe; R'=3,4-diMe (8f)	78	120-122
21	4b	R'=4-OMe (6g)	R= OMe; R'=4-OMe (8g)	78	112-114
22	4b	R'=3,4-diOMe (6h)	R= OMe; R'=3,4-diOMe (8h)	78	128-130
23	4b	R'=3,4-OCH ₂ O (6i)	R= OMe; R'=3,4-OCH ₂ O (8i)	76	165-168
24	4b	R'=3-F (6j)	R= OMe; R'=3-F (8j)	74	120-122
25	4b	R'=4-F (6k)	R= OMe; R'=4-F (8k)	74	110-112
26	4b	R'=3-Cl (6l)	R= OMe; R'=3-Cl (8l)	76	125-128
27	4b	R'=4-Cl (6m)	R= OMe; R'=4-Cl (8m)	77	123-125
28	4b	R'=4-Br (6n)	R= OMe; R'=4-Br (8n)	70	122-124
29	4c	R'=H (6a)	R=F; R' = H (9a)	82	108-110
30	4c	R'=4- <i>n</i> -Bu (6b)	R=F; R'=4- <i>n</i> -Bu (9b)	78	90-93
31	4c	R'=4- <i>i</i> -Pr (6c)	R=F; R'=4- <i>i</i> -Pr (9c)	78	160-161
32	4c	R'=4- <i>t</i> -Bu (6d)	R=F; R'=4- <i>t</i> -Bu (9d)	76	175-178
33	4c	R'=3,5-diMe (6e)	R=F; R'=3,5-diMe (9e)	76	178-180
34	4c	R'=3,4-diMe (6f)	R=F; R'=3,4-diMe (9f)	79	145-147
35	4c	R'=4-OMe (6g)	R=F; R'=4-OMe (9g)	77	142-144
36	4c	R'=3,4-diOMe (6h)	R=F; R'=3,4-diOMe (9h)	77	160-163
37	4c	R'=3,4-OCH ₂ O (6i)	R=F; R'=3,4-OCH ₂ O (9i)	74	180-182
38	4c	R'=3-F (6j)	R=F; R'=3-F (9j)	73	128-131
39	4c	R'=4-F (6k)	R=F; R'=4-F (9k)	74	148-150
40	4c	R'=3-Cl (6l)	R=F; R'=3-Cl (9l)	74	105-107
41	4c	R'=4-Cl (6m)	R=F; R'=4-Cl (9m)	82	109-110
42	4c	R'=4-Br (6n)	R=F; R'=4-Br (9n)	70	147-150

Conclusions

Syntheses of a number of new furoxan-3-thiazolidinones were successfully accomplished and are well characterized by spectral data. The anticancer activity of these compounds is being studied and will be reported in due course.

Experimental Section

General. All reactions involving air-sensitive reagents were performed under nitrogen atmosphere. Solvents were freshly dried and purified by conventional methods prior to use. The progress of all the reactions was monitored by TLC, using TLC aluminium sheets precoated with silica gel 60 F₂₅₄ to a thickness of 0.25 mm (Merck). Flash column chromatography was done using silica gel (Merck, 60-120 mesh). Melting points were determined on a MEL-TEMP II melting point apparatus. IR spectra were recorded on a Perkin-Elmer FT-IR spectrophotometer and expressed with (ν_{max} , cm^{-1}). ^1H and ^{13}C NMR spectra were recorded on a Varian Gemini 200 MHz, Bruker Avance 300 MHz spectrometer; TMS was used as an internal standard in $\text{CDCl}_3/\text{DMSO}-d_6$. Mass spectra were recorded on VG Micromass 7070 H (EI), QSTAR XL High resolution mass spectrometer (HRMS), Thermofinnigan ESI ion trap Mass Spectrometer and a GC-MS system on an Agilent 6890 series.

Furoxan aldehydes 4a-c: these were prepared as described.³⁷ Compound **4a**, mp 65-66 °C (lit. mp 64-65 °C); **4b**, mp 92-94 °C; **4c**, 74-76 °C (no lit.³⁷ mps were reported for **4b,c**).

General procedure for the preparation of furoxan-3-thiazolidinones. To the solution of furoxan aldehyde (2.5 mmol) in 10 mL toluene, was added aniline (2.75 mmol) in 10 mL of toluene at 0 °C. After formation of imine which is monitored by TLC, thioglycolic acid (10 mmol) was added to the reaction mixture at the same temperature. The reaction was stirred and heated at 50 °C for 4 h. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and washed with saturated solution of NaHCO_3 (3×20 mL). The combined organic layer was dried (Na_2SO_4), concentrated under reduced pressure. The crude products were purified using silica-gel column chromatography (eluent-3:2 hexane-ethyl acetate), to afford pure products.

3-(4-Oxo-3-phenylthiazolidin-2-yl)-4-phenyl-1,2,5-oxadiazole 2-oxide (7a). White solid (82%), m.p. 82-84 °C, IR (film): 2924, 2853, 1703, 1596, 1492, 1455, 1377, 1218, 834, 770 cm^{-1} . ^1H NMR (300 MHz, CDCl_3) δ 7.60-7.45 (m, 3H), 7.40-7.24 (m, 5H), 7.16-7.10 (m, 2H), 6.17 (s, 1H), 4.04 (brd, 1H, J 15.2 Hz), 3.77 (d, 1H, J 15.2 Hz). ^{13}C NMR (75 MHz, CDCl_3) δ 170.1, 155.7, 136.0, 131.3, 129.7, 129.2, 128.4, 127.9, 125.3, 125.1, 114.4, 54.6, 33.7. ESI-MS: m/z 362 ($\text{M}+\text{Na}$)⁺. HRMS (ESI): m/z [$\text{M} + \text{Na}$]⁺ Calcd for $\text{C}_{17}\text{H}_{13}\text{N}_3\text{O}_3\text{SNa}$: 362.0570; Found: 362.0588.

3-[3-(4-Butylphenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7b). White solid (77%), m.p. 100-102 °C, IR (film): 3036, 2927, 2856, 1693, 1594, 1453, 1341, 782, 759 cm^{-1} .

¹. ¹H NMR (300 MHz, CDCl₃) δ 7.55 (tt, 1H, *J* 7.4, 1.8 Hz), 7.50-7.45 (m, 2H), 7.24 (brd, 2H, *J* 7.4 Hz), 7.16 (dd, 2H, *J* 8.3 Hz), 7.02 (dd, 2H, *J* 8.3 Hz), 6.11 (s, 1H), 4.02 (brd, 1H, *J* 15.1 Hz), 3.74 (d, 1H, *J* 15.1 Hz), 2.57 (t, 2H, *J* 7.7 Hz), 1.62-1.52 (m, 2H), 1.36-1.26 (m, 2H), 0.90 (t, 3H, *J* 7.3 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 155.8, 143.6, 133.5, 131.3, 129.7, 129.2, 128.0, 125.3, 125.2, 114.4, 54.8, 35.1, 33.7, 33.2, 22.1, 13.8. ESI-MS: *m/z* 396 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₁H₂₂N₃O₃S: 396.1376; Found: 396.1380.

3-[3-(4-Isopropylphenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7c). White solid (75%), m.p. 160-164 °C, IR (film): 3385, 2964, 2368, 1701, 1591, 1224, 700 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.63-7.44 (m, 3H), 7.29-7.17 (m, 4H), 7.03 (d, 2H, *J* 8.3 Hz), 6.10 (s, 1H), 4.02 (brd, 1H, *J* 15.1 Hz), 3.74 (d, 1H, *J* 15.1 Hz), 2.88 (sept, 1H, *J* 6.7 Hz), 1.21 (d, 6H, *J* 6.7 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 155.8, 149.4, 133.5, 131.2, 129.2, 128.0, 127.8, 125.4, 125.2, 114.4, 54.7, 33.7 (2C), 23.7. ESI-MS: *m/z* 382 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₀H₂₀N₃O₃S: 382.1225; Found: 382.1229.

3-[3-(4-*tert*-Butylphenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7d). White solid (81%), m.p. 150-152 °C, IR (film): 3000, 2964, 2870, 1702, 1594, 772, 625 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.56 (tt, 1H, *J* 7.4, 1.8 Hz), 7.50-7.45 (m, 2H), 7.38-7.36 (m, 2H), 7.21 (brd, 2H, *J* 7.1 Hz), 7.06-7.03 (m, 2H), 6.11 (s, 1H), 4.01 (brs, 1H), 3.75 (d, 1H, *J* 15.1 Hz), 1.28 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 170.5, 155.8, 151.7, 133.0, 131.2, 129.1, 127.9, 126.6, 125.1, 125.0, 114.4, 64.0, 49.9, 30.9, 24.8. ESI-MS: *m/z* 396 (M+Na)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₁H₂₂N₃O₃S: 396.1379; Found: 396.1376.

3-[3-(3,5-Dimethylphenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7e). White solid (78%), m.p. 160-161 °C, IR (film): 2921, 2852, 1681, 1598, 1384, 1217, 1024, 860, 768 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.57 (tt, 1H, *J* 7.6, 1.8 Hz), 7.49 (m, 2H), 7.27 (brd, 2H, *J* 7.2 Hz), 6.92 (s, 1H), 6.70 (s, 2H), 6.13 (s, 1H), 4.05 (brd, 1H, *J* 14.6 Hz), 3.75 (d, 1H, *J* 14.6 Hz), 2.23 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 170.1, 155.9, 139.6, 135.8, 131.3, 130.3, 129.3, 128.1, 125.4, 123.1, 114.5, 54.8, 33.9, 21.2. ESI-MS: *m/z* 390 (M+Na)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₉H₁₈N₃O₃S: 368.1063; Found: 368.1056.

3-[3-(3,4-Dimethylphenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7f). White solid (78%), m.p. 145-147 °C, IR (film): 3421, 2922, 1594, 1136, 785, 631 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.59-7.55 (m, 1H), 7.49 (t, 2H, *J* 7.4 Hz), 7.28 (d, 2H, *J* 7.0 Hz), 7.11 (d, 1H, *J* 8.2 Hz), 6.87-6.84 (m, 2H), 6.13 (s, 1H), 3.75 (d, 1H, *J* 15.2 Hz), 2.22 (s, 3H), 2.18 (s, 3H), 4.02 (brs, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 170.1, 155.8, 138.3, 137.3, 133.5, 131.2, 130.7, 129.2, 128.0, 126.5, 125.3, 122.6, 114.4, 54.7, 33.8, 19.7, 19.4. ESI-MS: *m/z* 390 (M+Na)⁺. HRMS (ESI): *m/z* [M + Na]⁺ Calcd for C₁₉H₁₇N₃O₃SNa: 390.0890; Found: 390.0889.

3-[3-(4-Methoxyphenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7g). Brown solid (78%), m.p. 129-131 °C, IR (film): 2922, 2851, 1693, 1594, 1235, 1017, 840, 766, 699 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.61-7.54 (m, 1H), 7.53-7.46 (m, 2H), 7.30-7.24 (m, 2H), 7.05 (d, 2H, *J* 8.7 Hz), 6.87 (d, 2H, *J* 8.7 Hz), 6.08 (s, 1H), 4.05 (brd, 1H, *J* 13.9 Hz), 3.76 (d, 1H, *J* 13.9 Hz), 3.78 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 170.3, 159.3, 155.7, 131.2, 129.2, 128.4,

127.9, 127.0, 125.1, 114.9, 114.3, 55.3, 54.8, 33.6. ESI-MS: m/z 370 ($M+H$)⁺. HRMS (ESI): m/z [$M + H$]⁺ Calcd for C₁₈H₁₆N₃O₄S: 370.0856; Found: 370.0860.

3-[3-(3,4-Dimethoxyphenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7h).

White solid (77%), m.p. 120-124 °C, IR (film): 2926, 1692, 1585, 1216, 1017, 936, 768, 682 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.60-7.45 (m, 3H), 7.28 (d, 2H, J 7.5 Hz), 6.81 (d, 1H, J 8.4 Hz), 6.68 (dd, 1H, J 8.4, 2.2 Hz), 6.61 (d, 1H, J 2.2 Hz), 6.11 (s, 1H), 4.06 (brd, 1H, J 14.9 Hz), 3.86 (s, 3H), 3.77 (d, 1H, J 14.9), 3.74 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 155.7, 149.6, 149.0, 131.3, 129.3, 128.7, 128.0, 125.3, 118.0, 114.4, 111.4, 108.9, 55.9, 55.9, 54.8, 33.7. ESI-MS: m/z 400 ($M+H$)⁺. HRMS (ESI): m/z [$M + H$]⁺ Calcd for C₁₉H₁₈N₃O₅S: 400.0958; Found: 400.0955.

3-[3-(1,3-Benzodioxol-5-yl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7i).

White solid (77%), m.p. 121-123 °C, IR (film): 3003, 2965, 2930, 1697, 1591, 833, 779 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.58 (tt, 1H, J 1.9, 7.4 Hz), 7.53-7.49 (m, 2H), 7.32 (brd, 2H, J 7.3 Hz), 6.76 (d, 1H, J 8.2 Hz), 6.63 (d, 1H, J 1.9 Hz), 6.57 (dd, 1H, J 8.2, 1.9 Hz), 6.05 (s, 1H), 5.99-5.98 (m, 2H), 4.04 (brd, 1H, J 15.2 Hz), 3.75 (d, 1H, J 15.2 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.4, 155.6, 148.5, 147.7, 131.3, 129.5, 129.3, 127.9, 125.1, 119.4, 114.3, 108.6, 107.1, 101.8, 64.2, 33.6. ESI-MS: m/z 384 ($M+H$)⁺. HRMS (ESI): m/z [$M + H$]⁺ Calcd for C₁₈H₁₄N₃O₅S: 384.0648; Found: 384.0658.

3-[3-(3-Fluorophenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7j).

Brown solid (77%), m.p. 99-101 °C, IR (film): 2924, 1595, 1376, 1020 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.60 (tt, 1H, J 7.3, 1.3 Hz), 7.56-7.51 (m, 2H), 7.33 (brd, 2H, J 8.2 Hz), 7.32-7.29 (m, 1H), 7.00 (dt, 1H, J 7.4, 1.8 Hz), 6.94-6.89 (m, 2H), 6.19 (s, 1H), 3.99 (brd, 1H, J 15.4 Hz), 3.77 (d, 1H, J 15.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 169.9, 162.8 (d, J 249.2 Hz), 155.6, 137.5 (d, J = 9.9 Hz), 131.4, 130.8 (d, J = 8.8 Hz), 129.4, 128.0, 125.1, 120.1, 115.3 (d, J 21.5 Hz), 114.4, 112.6 (d, J 24.2 Hz), 54.4, 33.7. ESI-MS: m/z 358 ($M+H$)⁺. HRMS (ESI): m/z [$M + H$]⁺ Calcd for C₁₇H₁₃FN₃O₃S: 358.0656; Found: 358.0661.

3-[3-(4-Fluorophenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7k).

White solid (77%), m.p. 118-120 °C, IR (film): 3019, 2927, 1697, 1598, 1509, 1383, 1217, 825, 767 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.62-7.48 (m, 3H), 7.29 (brd, 2H, J 7.5 Hz), 7.14-7.00 (m, 4H), 6.13 (s, 1H), 4.04 (brd, 1H, J 15.1 Hz), 3.77 (d, 1H, J 15.1 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 161.8 (d, J 248.8 Hz), 155.6, 131.9 (d, J 2.7 Hz), 131.4, 129.4, 127.9, 127.5 (d, J 9.1 Hz), 125.1, 116.9 (d, J 24.7 Hz), 114.2, 54.6, 33.6. ESI-MS: m/z 358 ($M+H$)⁺. HRMS (ESI): m/z [$M + H$]⁺ Calcd for C₁₇H₁₃FN₃O₃S: 358.0656; Found: 358.0660.

3-[3-(3-Chlorophenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7l).

White solid (80%), m.p. 108-110 °C, IR (film): 2922, 2852, 1697, 1593, 1387, 1019, 769, 723, 692 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.63-7.50 (m, 3H), 7.32 (brd, 2H, J 6.9 Hz), 7.29-7.25 (m, 2H), 7.11 (s, 1H), 7.06-7.01 (m, 1H), 6.18 (s, 1H), 4.02 (brd, 1H, J 15.4 Hz), 3.76 (d, 1H, J 15.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 169.9, 155.6, 137.1, 135.1, 131.4, 130.5, 129.4, 128.3, 128.0, 125.3, 125.1, 122.8, 114.2, 54.3, 33.6. ESI-MS: m/z 374, ($M+H$)⁺. HRMS (ESI): m/z [$M + H$]⁺ Calcd for C₁₇H₁₃³⁵ClN₃O₃S: 374.0360; Found: 374.0369; Calcd for C₁₇H₁₃³⁷ClN₃O₃S: 376.0332; Found: 376.0336.

3-[3-(4-Chlorophenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7m). White solid (81%), m.p. 158-159 °C, IR (film): 2924, 2853, 1697, 1575, 1387, 761, 722 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.59 (tt, 1H, *J* 7.4, 1.3 Hz), 7.55-7.51 (m, 2H), 7.34-7.30 (m, 4H), 7.07 (d, 2H, *J* 8.6 Hz), 6.17 (s, 1H), 4.00 (brd, 1H, *J* 15.2), 3.76 (d, 1H, *J* 15.2 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 155.7, 137.1, 131.6, 130.7, 129.5, 128.5, 128.1, 125.4, 125.1, 123.0, 114.3, 54.4, 33.8. ESI-MS: *m/z* 374, (M+H)⁺. HRMS (ESI): *m/z* [M+H]⁺ Calcd for C₁₇H₁₃³⁵ClN₃O₃S: 374.0360; Found: 374.0370; Calcd for C₁₇H₁₃³⁷ClN₃O₃S: 376.0332; Found: 376.0335.

3-[3-(4-Bromophenyl)-4-oxothiazolidin-2-yl]-4-phenyl-1,2,5-oxadiazole 2-oxide (7n). Yellowish white solid (70%), m.p. 198-200 °C, IR (film): 3515, 3047, 2349, 1694, 1510, 1258, 1031 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.63-7.58 (m, 1H), 7.55-7.51 (m, 2H), 7.47 (d, 2H, *J* 8.6 Hz), 7.35-7.32 (m, 2H), 7.01 (d, 2H, *J* 8.6 Hz), 6.18 (s, 1H), 4.00 (brd, 1H, *J* 15.2 Hz), 3.76 (d, 1H, *J* 15.2 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 155.6, 135.0, 132.8, 131.5, 129.4, 128.0, 126.6, 125.1, 122.0, 114.3, 54.3, 33.7. ESI-MS: *m/z* 419 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₇H₁₃⁷⁹BrN₃O₃S: 417.9856; Found: 417.9869; Calcd for C₁₇H₁₃⁸¹BrN₃O₃S: 419.9841; Found: 419.9842.

4-(4-Methoxyphenyl)-3-(4-oxo-3-phenylthiazolidin-2-yl)-1,2,5-oxadiazole 2-oxide (8a). White solid (80%), m.p. 150-152 °C, IR (film): 3010, 2934, 2837, 1696, 1597, 1446, 1022, 838, 745 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.60-7.46 (m, 3H), 7.30-7.24 (m, 2H), 7.05 (d, 2H, *J* 8.7 Hz), 6.87 (d, 2H, *J* 8.7 Hz), 6.08 (s, 1H), 4.05 (brd, 1H, *J* 13.8 Hz), 3.78 (s, 3H), 3.76 (d, 1H, *J* 13.8 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.1, 161.9, 155.5, 136.1, 129.7, 129.5, 128.3, 125.3, 117.3, 114.7, 114.4, 55.4, 54.7, 33.8. ESI-MS: *m/z* 370 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₈H₁₆N₃O₄S: 370.0856; Found: 370.0858.

3-[3-(4-butylphenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8b). White solid (81%), m.p. 99-100 °C, IR (film): 2958, 2933, 2856, 1691, 1596, 1448, 1252, 838, 781 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.22-7.13 (m, 4H), 7.02 (d, 2H, *J* 8.3 Hz), 5.97 (d, 2H, *J* 8.3 Hz), 6.12 (s, 1H), 4.06 (brd, 1H, *J* 15.1 Hz), 3.86 (s, 3H), 3.75 (d, 1H, *J* 15.1 Hz), 2.57 (t, 2H, *J* 7.5 Hz), 1.66-1.50 (m, 2H), 1.38-1.25 (m, 2H), 0.90 (t, 3H, *J* 6.9 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 161.8, 155.5, 143.5, 133.5, 129.7, 129.5, 125.4, 117.4, 114.7, 114.4, 55.4, 54.8, 35.1, 33.8, 33.2, 22.2, 13.8. ESI-MS: *m/z* 448 (M+Na)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₂H₂₄N₃O₄S: 426.1482; Found: 426.1480.

3-[3-(4-Isopropylphenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8c). White solid (77%), m.p. 125-127 °C, IR (film): 3318, 2684, 1539, 1285, 1057, 757 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.29-7.14 (m, 4H), 7.04 (d, 2H, *J* 8.3 Hz), 6.97 (d, 2H, *J* 8.3 Hz), 6.12 (s, 1H), 4.05 (brd, 1H, *J* 15.1 Hz), 3.86 (s, 3H), 3.76 (d, 1H, *J* 15.1 Hz), 2.88 (sept, 1H, *J* 7.5 Hz), 1.21 (d, 6H, *J* 7.5 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 161.8, 155.6, 149.4, 133.6, 129.5, 127.8, 125.4, 117.3, 114.7, 114.5, 55.4, 54.8, 33.8, 33.7, 23.7. ESI-MS: *m/z* 412 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₁H₂₂N₃O₄S: 412.1312; Found: 412.1316.

3-[3-(4-*tert*-Butylphenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8d). White solid (81%), m.p. 126-128 °C, IR (film): 3369, 2930, 1697, 1591, 1252, 1091, 833 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.37 (d, 2H, *J* 8.5 Hz), 7.17 (brs, 2H), 7.05 (d, 2H, *J* 8.5

Hz), 6.97 (d, 2H, *J* 8.6 Hz), 6.12 (s, 1H), 4.04 (brs, 1H), 3.89 (s, 3H), 3.75 (d, 1H, *J* 15.2 Hz), 1.28 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 161.8, 155.6, 151.6, 133.3, 129.5, 126.7, 114.7, 117.4, 114.5, 125.0, 55.4, 54.8, 34.6, 33.8, 31.1. ESI-MS: *m/z* 426 [M+H]⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₂H₂₄N₃O₄S: 426.1482; Found: 426.1484.

3-[3-(3,5-Dimethylphenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8e). White solid (84%), m.p. 128-130 °C, IR (film): 3012, 2923, 2853, 1697, 1597, 1440, 1381, 1257, 1030, 836, 756 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.22 (d, 2H, *J* 5.9 Hz), 6.99 (dt, 2H, *J* 8.5, 2.1 Hz), 6.92 (brs, 1H), 6.71 (s, 2H), 6.13 (s, 1H), 4.07 (brs, 1H), 3.87 (s, 3H), 3.77 (d, 1H, *J* 15.1 Hz), 2.24 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 170.1, 161.8, 155.6, 139.5, 135.8, 130.2, 129.6, 123.0, 117.5, 114.7, 114.4, 55.4, 54.8, 33.9, 21.1. ESI-MS: *m/z* 398 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₀H₂₀N₃O₄S: 398.1169; Found: 398.1169.

3-[3-(3,4-Dimethylphenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8f). White solid (78%), m.p. 120-122 °C, IR (film): 3012, 2056, 1697, 1597, 1137, 836, 593 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.24 (d, 2H, *J* 7.7 Hz), 7.10 (d, 1H, *J* 7.7 Hz), 7.02-6.96 (m, 2H), 6.85 (m, 2H), 6.13 (s, 1H), 4.05 (brd, 1H, *J* 15.1 Hz), 3.87 (s, 3H), 3.76 (d, 1H, *J* 15.1 Hz), 2.21 (s, 3H), 2.18 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 161.8, 155.6, 138.3, 137.3, 133.6, 130.7, 129.6, 126.5, 122.6, 117.5, 114.7, 114.5, 55.4, 54.8, 33.8, 19.7, 19.4. ESI-MS: *m/z* 398 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₀H₂₀N₃O₄S: 398.1165; Found: 398.1162.

4-(4-Methoxyphenyl)-3-[3-(4-methoxyphenyl)-4-oxothiazolidin-2-yl]-1,2,5-oxadiazole 2-oxide (8g). White solid (78%), m.p. 112-114 °C, IR (film): 3009, 2936, 2840, 1695, 1590, 1448, 1025, 839, 745 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.21 (d, 2H, *J* 8.8 Hz), 7.04 (d, 2H, *J* 8.6 Hz), 6.98 (d, 2H, *J* 8.6 Hz), 6.86 (d, 2H, *J* 8.8 Hz), 6.08 (s, 1H), 4.06 (brd, 1H, *J* 14.9 Hz), 3.86 (s, 3H), 3.77 (s, 3H), 3.76 (d, 1H, *J* 14.9 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.4, 161.8, 159.4, 155.5, 129.5, 128.5, 127.1, 117.3, 115.0, 114.8, 114.4, 55.4, 54.9, 33.7. ESI-MS: *m/z* 400 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₉H₁₈N₃O₅S: 400.09617; Found: 400.0961.

3-[3-(3,4-Dimethoxyphenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8h). White solid (78%), m.p. 128-130 °C, IR (film): 3422, 2852, 1593, 1387, 1019, 692, 516 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.23 (d, 2H, *J* 8.6 Hz), 6.98 (d, 2H, *J* 8.6 Hz), 6.80 (d, 1H, *J* 8.4 Hz), 6.65 (dd, 2H, *J* 8.4, 2.2 Hz), 6.12 (s, 1H), 4.15-3.98 (m, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.82-3.73 (m, 4H). ¹³C NMR (75 MHz, CDCl₃) δ 170.3, 161.8, 155.5, 149.5, 148.9, 129.4, 128.6, 118.0, 117.3, 114.7, 114.4, 111.3, 108.8, 55.9, 55.8, 55.4, 54.9, 33.7. ESI-MS: *m/z* 430 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₂₀H₂₀N₃O₆S: 430.1059; Found: 430.1061.

3-[3-(1,3-Benzodioxol-5-yl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8i). Brown solid (76%), m.p. 165-168 °C, IR (film): 3012, 2921, 2851, 1694, 1599, 1470, 1385, 1216, 837, 758 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.25 (brd, 2H, *J* 8.3 Hz), 7.03-6.98 (m, 2H), 6.76 (d, 1H, *J* 8.3 Hz), 6.64 (d, 1H, *J* 2.2 Hz), 6.58 (dd, 1H, *J* 8.3, 2.2 Hz), 6.05 (s, 1H), 5.98 (s, 2H), 4.06 (brd, 1H, *J* 15.1 Hz), 3.87 (s, 3H), 3.75 (d, 1H, *J* 15.1 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.4, 161.9, 155.5, 148.5, 147.7, 129.6, 129.5, 119.4, 117.3, 114.8, 114.3, 108.6, 107.2,

101.9, 55.4, 55.0, 33.7. ESI-MS: m/z 414 $[M+H]^+$. HRMS (ESI): m/z $[M + H]^+$ Calcd for $C_{19}H_{16}N_3O_6S$: 414.0754; Found: 414.0752.

3-[3-(3-Fluorophenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8j). Brown solid (74%), m.p. 120-122 °C, IR (film): 2925, 2985, 1694, 1598, 1258, 1012, 760, 598 cm^{-1} . 1H NMR (300 MHz, $CDCl_3$) δ 7.33-7.27 (m, 3H), 7.03-6.97 (m, 3H), 6.95-6.89 (m, 2H), 6.20 (s, 1H), 4.03 (brd, 1H, J 15.1 Hz), 3.87 (s, 3H), 3.77 (d, 1H, J 15.1 Hz). ^{13}C NMR (75 MHz, $CDCl_3$) δ 170.0, 162.8 (d, J 248.8 Hz), 161.8, 155.4, 137.5 (d, J 9.9 Hz), 130.8 (d, J 9.1 Hz), 129.5, 120.2, 117.2, 115.3 (d, J 21.8 Hz), 114.9, 114.4, 112.7 (d, J 23.6 Hz), 55.4, 54.4, 33.7. ESI-MS: m/z 388 $(M+H)^+$. HRMS (ESI): m/z $[M + H]^+$ Calcd for $C_{18}H_{15}FN_3O_4S$: 388.0761; Found: 388.0767.

3-[3-(4-Fluorophenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8k). White solid (74%), m.p. 110-112 °C, IR (film): 3017, 2970, 2939, 1694, 1598, 1440, 1219, 1031, 837, 768 cm^{-1} . 1H NMR (300 MHz, $CDCl_3$) δ 7.24 (brd, 2H, J 8.6 Hz), 7.13-7.09 (m, 2H), 7.06-7.02 (m, 2H), 7.00 (d, 2H, J 8.6 Hz), 6.13 (s, 1H), 4.06 (brd, 1H, J 15.2 Hz), 3.87 (s, 3H), 3.77 (d, 1H, J 15.2 Hz). ^{13}C NMR (75 MHz, $CDCl_3$) δ 170.4, 161.9 (d, J 250.2 Hz), 160.2, 155.5, 132.0 (d, J 4.4 Hz), 129.5, 127.6 (d, J 8.8 Hz), 117.2, 116.9 (d, J 21.9 Hz), 114.9, 114.3, 55.5, 54.7, 33.7. ESI-MS: m/z 388 $(M+H)^+$. HRMS (ESI): m/z $[M + H]^+$ Calcd for $C_{18}H_{15}FN_3O_4S$: 388.0761; Found: 388.0767.

3-[3-(3-Chlorophenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8l). Brown solid (76%), m.p. 125-128 °C, IR (film): 2983, 2937, 2840, 1703, 1602, 1456, 1259, 840, 786 cm^{-1} . 1H NMR (300 MHz, $CDCl_3$) δ 7.31-7.24 (m, 4H), 7.13-7.11 (m, 1H), 7.05-7.00 (m, 3H), 6.18 (s, 1H), 4.05 (brd, 1H, J 15.8 Hz), 3.88 (s, 3H), 3.77 (d, 1H, J 15.8 Hz). ^{13}C NMR (75 MHz, $CDCl_3$) δ 170.1, 162.0, 155.5, 137.2, 135.2, 130.6, 129.6, 128.4, 125.5, 123.0, 117.1, 114.9, 114.3, 55.5, 54.4, 33.8. ESI-MS: m/z 404 $[M+H]^+$. HRMS (ESI): m/z $[M + H]^+$ Calcd for $C_{18}H_{15}^{35}ClN_3O_4S$: 404.0466; Found: 404.0470; Calcd for $C_{18}H_{15}^{37}ClN_3O_4S$: 406.0437; Found: 406.0434.

3-[3-(4-Chlorophenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8m). Brown solid (77%), m.p. 123-125 °C, IR (film): 3088, 2933, 2836, 1697, 1595, 1446, 1252, 836, 788 cm^{-1} . 1H NMR (300 MHz, $CDCl_3$) δ 7.34-7.28 (m, 4H), 7.08 (d, 2H, J 8.6 Hz), 7.02 (d, 2H, J 8.6 Hz), 6.18 (s, 1H), 4.04 (brd, 1H, J 15.2 Hz), 3.88 (s, 3H), 3.78 (d, 1H, J 15.2 Hz). ^{13}C NMR (75 MHz, $CDCl_3$) δ 170.1, 162.0, 155.4, 134.6, 134.0, 129.8, 129.5, 126.4, 117.2, 114.9, 114.3, 55.5, 54.5, 33.7. ESI-MS: m/z 404 $[M+H]^+$. HRMS (ESI): m/z $[M + H]^+$ Calcd for $C_{18}H_{15}^{35}ClN_3O_4S$: 404.0466; Found: 404.0469; Calcd for $C_{18}H_{15}^{37}ClN_3O_4S$: 406.0437; Found: 406.0435.

3-[3-(4-Bromophenyl)-4-oxothiazolidin-2-yl]-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide (8n). White solid (70%), m.p. 122-124 °C, IR (film): 3414, 2853, 1817, 1482, 1121, 759 cm^{-1} . 1H NMR (300 MHz, $CDCl_3$) δ 7.47 (d, 2H, J 8.6 Hz), 7.28 (d, 2H, J 8.6 Hz), 7.04-7.00 (m, 4H), 6.18 (s, 1H), 4.03 (brd, 1H, J 15.4 Hz), 3.88 (s, 3H), 3.77 (d, 1H, 15.4 Hz). ^{13}C NMR (75 MHz, $CDCl_3$) δ 170.1, 162.0, 155.4, 135.1, 132.8, 129.5, 126.6, 122.0, 117.2, 114.9, 114.3, 55.5, 54.4, 33.7. ESI-

MS: m/z 448 (M+H)⁺. HRMS (ESI): m/z [M+H]⁺ Calcd for C₁₈H₁₅⁷⁹BrN₃O₄S: 447.9992; Found: 447.9992; Calcd for C₁₈H₁₅⁸¹BrN₃O₄S: 449.9941; Found: 449.9948.

4-[4-Fluorophenyl]-3-(4-oxo-3-phenylthiazolidin-2-yl)-1,2,5-oxadiazole 2-oxide (9a). White solid (82%), m.p. 108-110 °C, IR (film): 3054, 2930, 2851, 1682, 1594, 1447, 1220, 840, 750, 696 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.39-7.35 (m, 2H), 7.33-7.29 (m, 1H), 7.28-7.24 (m, 2H), 7.21-7.17 (m, 2H), 7.13-7.10 (m, 2H), 6.14 (s, 1H), 4.04 (brd, 1H, *J* 15.4 Hz), 3.79 (d, 1H, *J* 15.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.1, 164.5 (d, *J* 252.5 Hz), 154.9, 136.0, 130.3 (d, *J* 8.8 Hz), 129.9, 128.6, 125.5, 121.4 (d, *J* 4.4 Hz), 116.8 (d, *J* 21.9 Hz), 114.3, 54.7, 33.8. ESI-MS: m/z 358 [M+H]⁺. HRMS (ESI): m/z [M + H]⁺ Calcd for C₁₇H₁₃FN₃O₃S: 358.0656; Found: 358.0659.

3-[3-(4-Butylphenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9b). White solid (78%), m.p. 90-93 °C, IR (film): 2926, 1692, 1597, 1216, 1039, 768 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.27-7.13 (m, 6H), 7.00 (d, 2H, *J* 8.3 Hz), 6.09 (s, 1H), 4.03 (d, 1H, *J* 15.2 Hz), 3.77 (d, 1H, *J* 15.2 Hz), 2.57 (t, 2H, *J* 7.7 Hz), 1.60-1.50 (m, 2H), 1.38-1.25 (m, 2H), 0.90 (t, 3H, *J* 7.7 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 164.4 (d, *J* 252.5 Hz), 155.0, 143.8, 133.5, 130.3 (d, *J* 8.8 Hz), 129.8, 125.4, 121.4, 116.7 (d, *J* 21.9 Hz), 114.3, 54.8, 35.2, 33.8, 33.3, 22.2, 13.9. ESI-MS: m/z 414 (M+H)⁺. HRMS (ESI): m/z [M+H]⁺ Calcd for C₂₁H₂₁FN₃O₃S: 414.1282; Found: 414.1274.

4-(4-Fluorophenyl)-3-[3-(4-isopropylphenyl)-4-oxothiazolidin-2-yl]-1,2,5-oxadiazole 2-oxide (9c). White solid (78%), m.p. 160-161 °C, IR (film): 3416, 2961, 1599, 1444, 1186, 842 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.24-7.19 (m, 4H), 7.18-7.13 (m, 2H), 7.02 (d, 2H, *J* 8.5 Hz), 6.09 (s, 1H), 4.03 (brd, 1H, *J* 15.1 Hz), 3.76 (d, 1H, *J* 15.1 Hz), 2.88 (sept, 1H, *J* 7.0 Hz), 1.21 (d, 6H, *J* 7.0 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 164.3 (d, *J* 253.4 Hz), 154.9, 149.5, 133.4, 130.2 (d, *J* 9.1 Hz), 127.8, 125.3, 121.3 (d, *J* 2.7 Hz), 116.5 (d, *J* 21.8 Hz), 114.2, 54.7, 33.6, 29.5, 23.7, 23.6. ESI-MS: m/z 400 (M+H)⁺. HRMS (ESI): m/z [M + H]⁺ Calcd for C₂₀H₁₉FN₃O₃S: 400.1131; Found: 400.1116.

3-[3-(4-*tert*-Butylphenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9d). White solid (76%), m.p. 175-178 °C, IR (film): 2992, 2965, 2934, 1696, 1589, 1384, 1222, 1020, 842, 782, 623 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.38 (d, 2H, *J* 8.6 Hz), 7.22-7.13 (m, 4H), 7.03 (d, 2H, *J* 8.6 Hz), 6.08 (s, 1H), 4.02 (brd, 1H, *J* 15.2 Hz), 3.77 (d, 1H, *J* 15.2 Hz), 1.28 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 170.1, 164.3 (d, *J* 253.4 Hz), 154.9, 151.8, 133.2, 130.3 (d, *J* 8.1 Hz), 126.8, 125.0, 121.4 (d, *J* 2.7 Hz), 116.6 (d, *J* 21.8 Hz), 114.3, 54.7, 34.6, 33.7, 31.1. ESI-MS: m/z 414 (M+H)⁺. HRMS (ESI): m/z [M + H]⁺ Calcd for C₂₁H₂₁FN₃O₃S: 414.1282; Found: 414.1276.

3-[3-(3,5-Dimethylphenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9e). White solid (76%), m.p. 178-180 °C, IR (film): 2920, 2854, 1689, 1603, 1453, 1231, 1030, 839, 733, 622 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.30-7.17 (m, 4H), 6.93 (brs, 1H), 6.72 (s, 2H), 6.10 (s, 1H), 4.05-4.00 (m, 1H), 3.74 (d, 1H, *J* 15.2 Hz), 2.24 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 169.9, 164.4 (d, *J* 253.6 Hz), 154.9, 139.6, 135.8, 130.4 (d, *J* 8.8 Hz), 130.2, 123.0, 121.6 (d, *J* 2.7 Hz), 116.6 (d, *J* 22.0 Hz), 114.2, 54.7, 33.8, 21.1. ESI-MS: m/z 386 (M+H)⁺. HRMS (ESI): m/z [M + H]⁺ Calcd for C₁₉H₁₇FN₃O₃S: 386.0969; Found: 386.0967.

3-[3-(3,4-Dimethylphenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9f). White solid (79%), m.p. 145-147 °C, IR (film): 3421, 1675, 1603, 1452, 839, 585 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.30-7.26 (m, 2H), 7.17 (dt, 2H, *J* 8.5, 1.8 Hz), 7.10 (d, 1H, *J* 7.9 Hz), 6.87-6.82 (m, 2H), 6.12 (s, 1H), 4.07-3.97 (m, 1H), 3.80-3.72 (m, 1H), 2.21 (s, 3H), 2.17 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 169.8, 164.1 (d, *J* 253.6 Hz), 154.8, 138.2, 137.2, 133.5, 130.6, 130.2 (d, *J* 8.8 Hz), 126.3, 122.5, 121.4 (d, *J* 2.7 Hz), 116.5 (d, *J* 22.0 Hz), 114.2, 54.6, 33.6, 19.5, 19.2. ESI-MS: *m/z* 386 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₉H₁₇FN₃O₃S: 386.0896; Found: 386.0963.

4-(4-Fluorophenyl)-3-[3-(4-methoxyphenyl)-4-oxothiazolidin-2-yl]-1,2,5-oxadiazole 2-oxide (9g). White solid (77%), m.p. 142-144 °C, IR (film): 3005, 2934, 2842, 1683, 1592, 1440, 1228, 836, 817, 773 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.31-7.24 (m, 2H), 7.22-7.14 (m, 2H), 7.03 (d, 2H, *J* 9.0 Hz), 6.87 (d, 2H, *J* 9.0 Hz), 6.05 (s, 1H), 4.05 (brd, 1H, *J* 15.2 Hz), 3.78 (s, 3H), 3.77 (d, 1H, *J* 15.2 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 164.4 (d, *J* 252.5 Hz), 159.4, 154.8, 130.3 (d, *J* 8.8 Hz), 128.4, 127.1, 121.4, 116.8 (d, *J* 21.9 Hz), 115.0, 114.2, 55.4, 54.8, 33.6. ESI-MS: *m/z* 388 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₈H₁₅FN₃O₄S: 388.0761; Found: 388.0758.

3-[3-(3,4-Dimethoxyphenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9h). White solid (77%), m.p. 160-163 °C, IR (film): 3353, 2966, 2044, 1684, 1445, 1099 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.33-7.26 (m, 2H), 7.23-7.15 (m, 2H), 6.81 (d, 1H, *J* 8.4 Hz), 6.67 (dd, 1H, *J* 8.4, 2.4 Hz), 6.62 (d, 1H, *J* 2.4 Hz), 6.08 (s, 1H), 4.06 (brd, 1H, *J* 15.4 Hz), 3.86 (s, 3H), 3.79 (d, 1H, *J* 15.4 Hz), 3.76 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 170.2, 164.4 (d, *J* 253.4 Hz), 154.9, 149.6, 149.0, 130.2 (d, *J* 8.2 Hz), 128.6, 121.4 (d, *J* 1.8 Hz), 117.9, 116.7 (d, *J* 22.7 Hz), 114.2, 111.3, 108.8, 55.9, 55.9, 54.8, 33.6. ESI-MS: *m/z* 418 [M+H]⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₉H₁₇FN₃O₅S: 418.0858; Found: 418.0860.

3-[3-(1,3-Benzodioxol-5-yl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9i). White solid (74%), m.p. 180-182 °C, IR (film): 3069, 2908, 1681, 1587, 1444, 1038, 845, 777, 628, 669 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.35-7.29 (m, 2H), 7.25-7.18 (m, 2H), 6.77 (d, 1H, *J* 8.3 Hz), 6.63 (d, 1H, *J* 2.2 Hz), 6.57 (dd, 1H, *J* 8.3, 2.2 Hz), 6.01 (s, 1H), 5.99 (s, 2H), 4.06 (brd, 1H, *J* 15.8 Hz), 3.77 (d, 1H, *J* 15.8 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.4, 163.8 (d, *J* 251.3 Hz), 148.6, 141.7, 140.8, 130.3 (d, *J* 8.8 Hz), 129.5, 119.5, 116.9 (d, *J* 21.9 Hz), 114.2, 108.8, 107.2, 102.0, 94.8, 54.9, 33.7. ESI-MS: *m/z* 402 [M+H]⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₈H₁₃FN₃O₅S: 402.0554; Found: 402.0546.

4-(4-Fluorophenyl)-3-[3-(3-fluorophenyl)-4-oxothiazolidin-2-yl]-1,2,5-oxadiazole 2-oxide (9j). White solid (73%), m.p. 128-131 °C, IR (film): 2928, 1680, 1387, 622, 567 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.36-7.30 (m, 3H), 7.25-7.21 (m, 2H), 7.03-6.99 (m, 1H), 6.93-6.89 (m, 2H), 6.17 (s, 1H), 4.01 (brd, 1H, *J* 15.4 Hz), 3.80 (d, 1H, *J* 15.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 165.0 (d, *J* 254.4 Hz), 162.9 (d, *J* 247.9 Hz), 164.5, 130.9 (d, *J* 8.8 Hz), 130.3 (d, *J* 8.8 Hz), 120.3 (d, *J* 4.4 Hz), 117.0 (d, *J* 21.9 Hz), 116.9, 115.8 (d, *J* 21.9 Hz), 115.4, 114.3, 112.7 (d, *J* 24.1 Hz), 54.4, 33.8. ESI-MS: *m/z* 376 [M+H]⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₇H₁₂F₂N₃O₃S: 376.0561; Found: 376.0566.

4-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-4-oxothiazolidin-2-yl]-1,2,5-oxadiazole 2-oxide (9k). White solid (74%), m.p. 148-150 °C, IR (film): 3075, 2927, 2852, 1681, 1595, 1508, 1387, 1217, 843, 776, 619, 588 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.34-7.28 (m, 2H), 7.24-7.19 (m, 2H), 7.13-7.08 (m, 2H), 7.08-7.02 (m, 2H), 6.11 (s, 1H), 4.05 (brd, 1H, *J* 15.2 Hz), 3.79 (d, 1H, *J* 15.2 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.3, 164.6 (d, *J* 254.7 Hz), 162.0 (d, *J* 248.1 Hz), 154.8, 131.9 (d, *J* 4.4 Hz), 130.7 (d, *J* 8.8 Hz), 127.5 (d, *J* 6.6 Hz), 121.3, 117.0 (d, *J* 21.9 Hz), 116.8 (d, *J* 21.9 Hz), 114.1, 54.7, 33.6. ESI-MS: *m/z* 376 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₇H₁₂F₂N₃O₃S: 376.0561; Found: 376.0564.

3-[3-(3-Chlorophenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9l). White solid (74%), m.p. 105-107 °C, IR (film): 3001, 2929, 1599, 1444, 850, 618 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.35-7.31 (m, 2H), 7.29-7.26 (m, 2H), 7.24-7.20 (m, 2H), 7.11-7.10 (m, 1H), 7.04-7.01 (m, 1H), 6.17 (s, 1H), 4.03 (brd, 1H, *J* 15.4 Hz), 3.78 (d, 1H, *J* 15.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 166.2 (d, *J* 252.4 Hz), 154.8, 137.1, 135.3, 130.7, 130.4 (d, *J* 8.8 Hz), 128.6, 125.4, 123.0, 121.2, 116.9 (d, *J* 21.9 Hz), 114.2, 54.4, 33.7. ESI-MS: *m/z* 392 (M+H)⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₇H₁₂F³⁵ClN₃O₃S: 392.0266; Found: 392.0269; Calcd for C₁₇H₁₂F³⁷ClN₃O₃S: 394.0237; Found: 394.0234.

3-[3-(4-Chlorophenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9m). White solid (82%), m.p. 109-110 °C, IR (film): 2974, 2929, 2851, 1686, 1601, 1445, 1384, 1217, 842, 786, 620 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.36-7.31 (m, 4H), 7.25-7.20 (m, 2H), 7.08-7.05 (m, 2H), 6.15 (s, 1H), 4.01 (d, 1H, *J* 15.4 Hz), 3.79 (d, 1H, *J* 15.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 164.4 (d, *J* 254.68 Hz), 154.7, 134.3 (d, *J* 21.9 Hz), 130.3 (d, *J* 8.8 Hz), 130.0, 129.0, 126.4, 121.3, 116.9 (d, *J* 21.9 Hz), 114.2, 54.4, 33.7. ESI-MS: *m/z* 392 [M+H]⁺. HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₁₇H₁₂F³⁵ClN₃O₃S: 392.0266; Found: 392.0269. Calcd for C₁₇H₁₂F³⁷ClN₃O₃S: 394.0237; Found: 394.0235.

3-[3-(4-Bromophenyl)-4-oxothiazolidin-2-yl]-4-(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (9n). Brown solid (70%), m.p. 147-150 °C, IR (film): 3356, 2929, 1686, 1443, 1287, 1162, 587 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ 7.48 (d, 2H, *J* 8.6 Hz), 7.38-7.32 (m, 2H), 7.26-7.19 (m, 2H), 7.01 (d, 2H, *J* 8.6 Hz), 6.16 (s, 1H), 4.01 (d, 1H, *J* 15.4 Hz), 3.79 (d, 1H, *J* 15.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 169.9, 164.1 (d, *J* 254.7 Hz), 154.8, 134.9, 132.9, 130.3 (d, *J* 8.7 Hz), 126.6, 122.1, 121.3, 116.9 (d, *J* 21.9 Hz), 114.3 54.3, 33.6. ESI-MS: *m/z* 459 [M+Na]⁺. HRMS (ESI): *m/z* [M + Na]⁺ Calcd for C₁₇H₁₁F⁷⁹BrN₃O₃SNa: 457.9581; Found: 457.9585; Calcd for C₁₇H₁₁F⁸¹BrN₃O₃SNa: 459.9561; Found: 459.9555.

Acknowledgements

The authors thank the Director, IICT for support. 12th 5 Yr Plan Project ORIGIN-CSC-0108 is acknowledged for financial assistance. SNK, CHNSSPK thank CSIR-New Delhi, SRVA thank NIPER-HYD, KKS thank DST-INSPIRE for the fellowship.

References

1. Gasco, A.; Boulton, A. J. *Adv. Heterocycl. Chem.*, **1981**, 29, 251.
[http://dx.doi.org/10.1016/S0065-2725\(08\)60789-8](http://dx.doi.org/10.1016/S0065-2725(08)60789-8)
2. Cerecetto, H.; Porcal, W. *Mini Rev. Med. Chem.*, **2005**, 5, 57.
<http://dx.doi.org/10.2174/1389557053402864>
3. Khmelnitskii, L. I.; Novikov, S. S.; Godovikova, T. I. *Chemistry of Furoxans: Reactions and Applications* 2nd ed., M. Nauka, (in Russian) **1996**.
4. Bohn, H.; Brendel, J.; Martorana, P. A.; Schönafinger, K. *Br. J. Pharmacol.*, **1995**, 114, 1605.
<http://dx.doi.org/10.1111/j.1476-5381.1995.tb14946.x>
5. Sayed, A. A.; Simeonov, A.; Thomas, C. J.; Inglese, J.; Austin, C. P.; Williams, D. L. *Nat. Med.*, **2008**, 14, 407.
<http://dx.doi.org/10.1038/nm1737>
6. Wang, P. G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A. J. *Chem. Rev.*, **2002**, 102, 1091.
<http://dx.doi.org/10.1021/cr000040l>
7. Vo, D.; Nguyen, J. -T.; McEwen, C. -A.; Shan, R.; Knaus, E. E. *Drug Dev. Res.*, **2002**, 56, 1.
<http://dx.doi.org/10.1002/ddr.10050>
8. Boschi, D.; Tron, G. C.; Stilo, A. D.; Fruttero, R.; Gasco, A.; Poggesi, E.; Motta, G.; Leonardi, A. *J. Med. Chem.*, **2003**, 46, 3762.
<http://dx.doi.org/10.1021/jm030825u>
9. Sorba, G.; Galli, U.; Cena, C.; Fruttero, R.; Gasco, A.; Morini, G.; Adami, M.; Coruzzi, G.; Brenciaglia, M. I.; Dubini, F. *Chem. Bio. Chem.*, **2003**, 4, 899.
<http://dx.doi.org/10.1002/cbic.200300617>
10. Tripathi, A. C.; Gupta, S. J.; Fatima, G. N.; Sonar, P. K.; Verma, A.; Saraf, S. K. *Eur. J. Med. Chem.*, **2014**, 72, 52.
<http://dx.doi.org/10.1016/j.ejmech.2013.11.017>
11. Verma, A.; Saraf, S. K. *Eur. J. Med. Chem.*, **2008**, 43, 897.
<http://dx.doi.org/10.1016/j.ejmech.2007.07.017>
12. Revelant, G.; Huber-Villaume, S.; Dunand, S.; Kirsch, G.; Schohn, H.; Hesse, S. *Eur. J. Med. Chem.*, **2015**, 94, 102.
<http://dx.doi.org/10.1016/j.ejmech.2015.02.053>
13. Nepali, K.; Sharma, S.; Sharma, M.; Bedi, P. M. S.; Dhar, K. L. *Eur. J. Med. Chem.*, **2014**, 77, 422.
<http://dx.doi.org/10.1016/j.ejmech.2014.03.018>
14. Ergenç, N.; Capan, G. *Farmaco*, **1994**, 49, 133.

15. Ulusoy, N.; Ergenç, N.; Ekinçi, A. C.; Özer, H. *Monatsh. Chem.*, **1996**, *127*, 1197.
<http://dx.doi.org/10.1007/BF00844695>
16. Ragab, F. A.; Eid, N. M.; el-Tawab, H. A. *Pharmazie*, **1997**, *52*, 926.
17. Giri, S.; Shukla, A. K.; Nizamuddin. *J. Indian. Pharm. Sci.*, **1990**, *52*, 108.
18. Cesur, N.; Cesur, Z.; Ergenç, N.; Uzun, M.; Kiraz, M.; Kasimoglu, O.; Kaya, D. *Arch. Pharm.*, **1994**, *327*, 271.
<http://dx.doi.org/10.1002/ardp.19943270414>
19. Karali, N.; İlhan, E.; Gursoy, A.; Kiraz, M. *Farmaco*, **1998**, *53*, 346.
[http://dx.doi.org/10.1016/S0014-827X\(98\)00032-9](http://dx.doi.org/10.1016/S0014-827X(98)00032-9)
20. Babaoglou, K.; Page, M. A.; Jones, V. C.; McNeil, M. R.; Dong, C.; Naismith, J. H.; Lee, R. E. *Bioorg. Med. Chem. Lett.*, **2003**, *13*, 3227.
[http://dx.doi.org/10.1016/S0960-894X\(03\)00673-5](http://dx.doi.org/10.1016/S0960-894X(03)00673-5)
21. Ulsoy, N. *Arzneim.-Forsch./Drug. Res.*, **2002**, *52*, 565.
22. Anders, C. J.; Bronson, J. J.; Andrea, S. V.; Deshpande, M. S.; Falk, P. J.; Grant-Young, K. A.; Harte, E. W.; Ho, H. T.; Misco, P. F.; Robertson, J. G.; Stock, D.; Sun. Y.; Walsh, A. W. *Bioorg. Med. Chem.*, **2000**, *10*, 715.
23. Mahran, M. A.; El-Nassy, S. M. F.; Allam, S. R. *Pharmazie*, **2003**, *58*, 527.
24. Suzuki, M.; Morita, K.; Yukioka, H.; Miki, N.; Mizutani, A. *J. Pestic. Sci.*, **2003**, *28*, 37.
<http://dx.doi.org/10.1584/jpestics.28.37>
25. El-Ansary, A. K.; Omar, A. H. *Bull. Fac. Pharm. Cairo Univ.*, **2001**, *39*, 17; *Chem. Abstr.*, **2001**, *136*, 216712h.
26. Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Filippeli, W.; Falcone, G.; Giordano, L.; Vitelli, M. R. *Bioorg. Med. Chem.*, **2001**, *9*, 2149.
[http://dx.doi.org/10.1016/S0968-0896\(01\)00121-3](http://dx.doi.org/10.1016/S0968-0896(01)00121-3)
27. Bhatt, J.; Shah, B. R.; Shah, H. P.; Trivedi, P. B.; Undavia, N. K.; Desai, N. C. *Indian J. Chem.*, **1994**, *33B*, 189.
28. Gududuru, V.; Hurth, E.; Dalton, J. T.; Miller, D. D. *J. Med. Chem.*, **2005**, *48*, 2584.
<http://dx.doi.org/10.1021/jm049208b>
29. Küçükgülzel, G.; Kocatepe, A.; Clercq, E. D.; Sahin, F.; Güllüce, M. *Eur. J. Med. Chem.*, **2006**, *41*, 353.
<http://dx.doi.org/10.1016/j.ejmech.2005.11.005>
30. Tenorio, R. P.; Carvalho, C. S.; Pessanha, C. S.; Lima, J. G. De.; Edesiot, A. J.; Melo, J. T.; Goes, A. J. S. *Bioorg. Med. Chem.*, **2005**, *15*, 2575.
31. Bonde, C. G.; Gaikwad, N. J. *Bioorg. Med. Chem.*, **2004**, *12*, 2151.
<http://dx.doi.org/10.1016/j.bmc.2004.02.024>
32. Barreca, M. L.; Chimirri, A.; Luca, L. D.; Monforte, A -M.; Monforte, P.; Rao, A.; Zappalà, M.; Balzarini, J.; Clercq, E. D.; Pannecouque, C.; Witvrouw, M. *Bioorg. Med. Chem. Lett.*, **2001**, *11*, 1793.
[http://dx.doi.org/10.1016/S0960-894X\(01\)00304-3](http://dx.doi.org/10.1016/S0960-894X(01)00304-3)

33. Rawal, R. K.; Prabhakar, Y. S.; Katti, S. B.; Clercq, D. *Bioorg. Med. Chem.*, **2005**, *13*, 6771.
<http://dx.doi.org/10.1016/j.bmc.2005.07.063>
34. Dayam, R.; Sanchez, T.; Clement, O.; Shoemaker, R.; Sei, S.; Nemati, N. *J. Med. Chem.*, **2005**, *48*, 111.
<http://dx.doi.org/10.1021/jm0496077>
35. Kumar, C. N. S. S. P.; Parida, D. K.; Santhoshi, A.; Kota, A. K.; Sridhar, B.; Jayathirtha Rao, V. *Med Chem Comm.*, **2011**, *2*, 486 and references cited therein.
<http://dx.doi.org/10.1039/c0md00263a>
36. Narender Reddy, T.; Ravinder, M.; Bagul, P.; Ravikanti, K.; Bagul, C.; Nanubolu, J. B.; Srinivas, K.; Banarjee, S. K.; Jayathirtha Rao, V. *Eur. J. Med. Chem.*, **2014**, *71*, 53 and references cited therein.
<http://dx.doi.org/10.1016/j.ejmech.2013.10.043>
37. Gasco, A. M.; Fruttero, R.; Sorba, G.; Gasco, A. *Liebigs Ann. Chem.*, **1991**, 1211.
<http://dx.doi.org/10.1002/jlac.1991199101207>
38. SMART & SAINT. Software Reference manuals. Versions 6.28a & 5.625, Bruker Analytical X-ray Systems Inc., Madison, Wisconsin, U.S.A., 2001.
39. Sheldrick, G. M. SHELXS97 and SHELXL97, Programs for crystal structure solution and refinement; University of Gottingen: Germany, 1997.